KrishPatelMD

Oncology • Nashville, TN

Hematologic Oncology

Director of Lymphoma Research Program, Sarah Cannon Research Institute Medical Oncologist, SCRI Oncology Partners

Join to view full profile

Dr. Patel is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Patel's full profile

Already have an account?

Office
335 24th Ave N
Ste 1020
Nashville, TN 37203
Phone+1 206-215-6196

Fax+1 206-215-1655

Summary

I am a board certified hematologist and medical oncologist who specializes in hematologic malignancies and cellular therapies. I have a particular focus in the care of patients with lymphoma and CLL and actively participate in developing novel therapies for these patients through early stage clinical trials.

Education & Training

Duke University HospitalFellowship, Hematology and Medical Oncology, 2012 - 2016
Duke University HospitalResidency, Internal Medicine, 2009 - 2012
Duke University School of MedicineClass of 2009

Certifications & Licensure

TN State Medical License 2024 - 2027
WA State Medical License 2016 - 2025
NC State Medical License 2009 - 2017
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Alpha Omega Alpha
Chief Resident, Internal Medicine, Duke University Hospital Duke University Hospital, 2013-2014
NIH Clinical Research Training Program National Institutes of Health - NCI, 2007-2008

Clinical Trials

Study to Assess the Safety, Tolerability and Pharmacokinetics of Fimepinostat (CUDC-907) in Patients With Lymphoma Start of enrollment: 2012 Dec 01
Completed
Phase 1
Study to Evaluate Safety and Tolerability of XmAb13676 (Plamotamab) in Patients With CD20-expressing Hematologic Malignancies Start of enrollment: 2016 Oct 01
Active, not recruiting
Phase 1
A Study of Durvalumab in Combination With R-CHOP or Lenalidomide Plus R-CHOP in Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma Start of enrollment: 2017 Feb 28
Completed
Phase 2
Safety, PK, PD, and Antitumor Activity of Vecabrutinib (SNS-062) in B Lymphoid Cancers Start of enrollment: 2017 Apr 28
Terminated
Phase 1, Phase 2
A Study of CA-4948 in Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma Start of enrollment: 2017 Dec 28
Recruiting
Phase 1, Phase 2
A Clinical Trial to Learn About the Study Medicine Called Maplirpacept (PF-07901801), Alone and When Used in Combination With Other Medicines to Treat Participants With Advanced Hematological Malignancies, Including Lymphoma, Leukemia and Multiple Myeloma Start of enrollment: 2018 Jun 07
Active, not recruiting
Phase 1
Acalabrutinib Plus RICE for Relapsed/Refractory DLBCL Start of enrollment: 2019 Aug 16
Recruiting
Phase 2
A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Hematologic Malignancies (MK-2140-001) Start of enrollment: 2019 Mar 14
Completed
Phase 1
Safety and Efficacy of Axicabtagene Ciloleucel in Combination With Rituximab in Participants With Refractory Large B-Cell Lymphoma Start of enrollment: 2019 Nov 05
Completed
Phase 2
FT516 in Subjects With Advanced Hematologic Malignancies Start of enrollment: 2019 Oct 04
Terminated
Phase 1
A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of RO7227166 in Combination With Obinutuzumab and in Combination With Glofitamab Following a Pre-Treatment Dose of Obinutuzumab Administered in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma Start of enrollment: 2019 Aug 13
Recruiting
Phase 1
Oral Tazemetostat in Combination With Rituximab in R/R FL Start of enrollment: 2020 Nov 17
Terminated
Phase 2
A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies Start of enrollment: 2021 May 05
Active, not recruiting
Phase 1
FT596 as a Monotherapy and in Combination With Anti-CD20 Monoclonal Antibodies Start of enrollment: 2020 Mar 19
Terminated
Phase 1
Study of Oral LOXO-338 in Patients With Advanced Blood Cancers Start of enrollment: 2021 Sep 30
Active, not recruiting
Phase 1
A Dose Finding Study of CC-96673 in Participants With Relapsed or Refractory Non-Hodgkin's Lymphoma Start of enrollment: 2022 Jan 20
Active, not recruiting
Phase 1
A Safety and Efficacy Study Evaluating CTX110 in Subjects With Relapsed or Refractory B-Cell Malignancies (CARBON) Start of enrollment: 2019 Jul 22
Active, not recruiting
Phase 1, Phase 2
Phase 2 Study of Plamotamab Combined With Tafasitamab Plus Lenalidomide Versus Tafasitamab Plus Lenalidomide in Relapsed or Refractory (R/R) Diffuse Large-cell B-cell Lymphoma (DLBCL) Start of enrollment: 2022 Apr 15
Terminated
Phase 2
A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL Start of enrollment: 2018 Nov 16
Active, not recruiting
Phase 1, Phase 2
SYMPHONY-2, A Trial to Examine Combination of Tazemetostat With Rituximab in Subjects With Relapsed/Refractory Follicular Lymphoma Start of enrollment: 2020 Dec 15
Terminated
Phase 2
A Study of CNTY-101 in Participants With CD19-Positive B-Cell Malignancies Start of enrollment: 2023 Jan 24
Recruiting
Phase 1
AZD4573 as Monotherapy or in Combinations With Anti-cancer Agents in Patients With r/r PTCL or r/r cHL Start of enrollment: 2021 Dec 15
Completed
Phase 2
A Study of CC-97540, CD-19-Targeted Nex-T CAR T Cells, in Participants With Severe, Refractory Autoimmune Diseases Start of enrollment: 2023 Sep 13
Recruiting
Phase 1
CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER) Start of enrollment: 2021 May 26
Recruiting
Phase 1
A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma Start of enrollment: 2022 Jun 14
Recruiting
Phase 2
A Study for Participants Previously Treated With Century Therapeutics Cellular Therapy Product Start of enrollment: 2024 Apr 29
Recruiting
Roles: Contact
A Phase 1 Study of ADI-001 in B Cell Malignancies Start of enrollment: 2021 Mar 04
Recruiting
Phase 1
Roles: Contact
A Phase 2 Study of Firi-cel in Patients With Relapsed/Refractory Large B-cell Lymphoma Start of enrollment: 2023 Aug 01
Recruiting
Phase 2
Study Evaluating SC262 in Subjects With r/r Non-Hodgkin's Lymphoma (VIVID) Start of enrollment: 2024 May 01
Recruiting
Phase 1
Join now to see all

Publications & Presentations

PubMed

Pirtobrutinib monotherapy in Bruton tyrosine kinase inhibitor-intolerant patients with B-cell malignancies: results of the phase I/II BRUIN trial.
Nirav N Shah, Michael Wang, Lindsey E Roeker, Krish Patel, Jennifer A Woyach
Haematologica. 2024-10-03
Safety and efficacy of acalabrutinib plus bendamustine and rituximab in patients with treatment-naive or relapsed / refractory mantle cell lymphoma: phase Ib trial.
Tycel Phillips, Michael Wang, Tadeusz Robak, David Gallinson, Don Stevens
Haematologica. 2024-09-05
Medicare Utilization and Cost Trends for CAR T Cell Therapies Across Settings of Care in the Treatment of Diffuse Large B-Cell Lymphoma.
James Wu, Armin Ghobadi, Richard Maziarz, Krish Patel, Hil Hsu
Advances in Therapy. 2024-08-01

Books/Book Chapters

Oncologic Emergency Medicine: Principles and Practice
Chapter: Rapid Learning Systems
Page 79 - 93Patel K, Abernethy A, Todd HK, Thomas Jr CRSpringer International Publishin

Abstracts/Posters

The Chronic Lymphocytic Leukemia Comorbidity Index (CLL-CI): A Novel Comorbidity Score Derived from a Large Multicenter Retrospective Cohort Study of Patients Treated ...
Krish Patel, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
A Multi-Center Dose-Finding Study to Assess Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Fimepinostat (CUDC-907) in Combination with Venetoclax i...
Krish Patel, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Toxicities and Outcomes of Acalabrutinib-Treated Patients with Chronic Lymphocytic Leukemia: A Retrospective Analysis of Real World Patients
Krish Patel, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
North American Practice Patterns for PET-2 Positive Hodgkin Lymphoma
Krish Patel, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Ongoing Results of a Phase 1B/2 Dose-Escalation and Cohort-Expansion Study of the Selective, Noncovalent, Reversible BrutonÍS Tyrosine Kinase Inhibitor, Vecabrutinib, ...
Krish Patel, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
A Phase 2, Open-Label, Multicenter Study Evaluating the Safety and Efficacy of Axicabtagene Ciloleucel in Combination with Either Rituximab or Lenalidomide in Patients...
Patel Krish, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Join now to see all

Lectures

Preliminary Safety and Anti-Tumor Activity of XmAb13676, an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Non-HodgkinÍs Lymphoma and C...
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
How I Think, How I Treat - BTK Inhibitors as a Clinical Strategy in CLL, MCL, and Beyond: Therapeutic Selection, Sequencing, and Next Steps
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
A Single Center Retrospective Study of Real World Relapsed/Refractory DLBCL Patients Eligible for CAR T-Cell Therapy: Patient Characteristics and Outcomes
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

Treatment Options in MCL: What Are the Best Practices?September 12th, 2024
$Xencor Presents Data from Phase 1 Study of Plamotamab in Relapsed or Refractory Non-Hodgkin Lymphoma at the American Society of Hematology Annual Meeting$
Xencor Presents Data from Phase 1 Study of Plamotamab in Relapsed or Refractory Non-Hodgkin Lymphoma at the American Society of Hematology Annual MeetingDecember 12th, 2022
$Xencor Presents Data from Plamotamab Phase 1 Study in Relapsed or Refractory Non-Hodgkin’s Lymphoma at American Society of Hematology Annual Meeting$
Xencor Presents Data from Plamotamab Phase 1 Study in Relapsed or Refractory Non-Hodgkin’s Lymphoma at American Society of Hematology Annual MeetingDecember 12th, 2022
Join now to see all